Enanta Pharmaceuticals Inc (ENTA)

[DC15]

When the challenge results for the first RSV antiviral were announced the stock quickly tanked and most of the publicity called the trial a failure. I agree that the market value is at all time lows, but I am cautious because selling ENTA for year end tax losses indicates that there is not much belief that any of those "free shots" are going to pan-out in the near future, i.e., there is a belief that there is plenty of time to make purchases of ENTA after first profiting form other near term purchases.

I bought on the positive news of the first RSV challenge study, I already had an accumulation of shares going back as far as 2015; I was baffled when all of the negative responses to the challenge study were vocalized.

That is my sad, sad story. I continue to have a lot of hope for Enanta, but my new expectations are that I have spent enough money, I am still faithful to my belief that the company is quite valuable far beyond my average cost, and I accept that any new investments for me are likely better spent on other equities which have demonstrated better trends in response to positive news.

Merry, Merry,
Sinking-and-Stinking-On-Positive-News